Annual financial results for financial year ended March 31, 2025
FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fermenta Biotech reported a strong turnaround for FY25. Standalone revenue from operations rose to Rs. 430.53 crore from Rs. 307.09 crore in FY24, a growth of about 40%. Standalone profit after tax swung from a loss of Rs. 18.55 crore in FY24 to a profit of Rs. 66.87 crore in FY25. Consolidated revenue grew to Rs. 469.48 crore from Rs. 335.66 crore, with consolidated PAT at Rs. 74.50 crore versus a loss of Rs. 24.16 crore. The board recommended a final dividend of Rs. 2.50 per share (50%) subject to shareholder approval, with record date August 6, 2025 and payment by August 22, 2025. The auditor SRBC & Co LLP issued an unmodified (clean) opinion on both standalone and consolidated results. Results include exceptional items of Rs. 9 crore (standalone) and Rs. 7.43 crore (consolidated). AGM is scheduled for August 12, 2025.
Positive for shareholders — sharp revenue growth, return to profitability, and a 50% dividend signal strong business recovery and improved earnings power, likely to be viewed favorably by the market.